Overall rank by patents
#39,495
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Cantex Pharmaceuticals, Inc.
USPTO PatentsView assignee record - 6 granted patents across 3 technology areas, active 2016–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
6
Total patents granted
3
CPC technology areas
18.5
Avg claims per patent
+0%
5-year filing velocity
The verdict
Cantex holds 6 US patents across 3 technology areas, rank #39,495 of 50,000 tracked assignees.
- #39,495
- of 50,000 US assignees by volume
- Top 65%
- by Innovation Score (30.6/100)
- 18.5
- avg claims per patent
- +0%
- filing velocity, last 5 yrs
Portfolio overview
Cantex Pharmaceuticals, Inc. has been granted 6 US utility patents between 2016 and 2023, placing Cantex Pharmaceuticals, Inc. at rank #39,495 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.5 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Cantex Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Cantex sits between Can-am Tool Corp. (6 patents, rank #39,491) and Capital Hardware Supply, Llc (6 patents, rank #39,499) - the closest US assignees by grant volume. The composite Innovation Score of 30.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 3 grants, compared with 3 in the 2015–2019 window, a +0% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Cantex Pharmaceuticals, Inc.'s 18.5 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Cantex Pharmaceuticals, Inc. against peers pursuing similar technology classes.
Who files at Cantex's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Can-am Tool
Can-Am Tool Corp.
6 patents
- Canary Capital
Canary Capital LLC
6 patents
- Cancer Intelligen…
Cancer Intelligence Care Systems, Inc.
6 patents
- Cantel (UK)
Cantel (UK) Limited
6 patents
- Canyon IP Holdings
Canyon IP Holdings, LLC
6 patents
- Canyon Oak Energy
Canyon Oak Energy LLC
6 patents
- Capewell Aerial S…
Capewell Aerial Systems LLC
6 patents
- Capital Hardware…
Capital Hardware Supply, LLC
6 patents
- Cantex Pharmaceut… ◀
Cantex Pharmaceuticals, Inc.
6 patents
What this shows Cantex holds 6 patents at rank #39,495, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Cantex
By rank, the assignees closest to #39,495 in granted patent volume.
- Can-am Tool Corp. #39,491 · 6 patents
- Canary Capital Llc #39,492 · 6 patents
- Cancer Intelligence Care Systems, Inc. #39,493 · 6 patents
- Cantel (uk) Limited #39,494 · 6 patents
- Canyon IP Holdings, Llc #39,496 · 6 patents
- Canyon Oak Energy Llc #39,497 · 6 patents
- Capewell Aerial Systems Llc #39,498 · 6 patents
- Capital Hardware Supply, Llc #39,499 · 6 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Cantex's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Cantex's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
31 Top 65% higher than 35% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 16.7% |
| 2018 | 1 | 16.7% |
| 2019 | 1 | 16.7% |
| 2021 | 1 | 16.7% |
| 2022 | 1 | 16.7% |
| 2023 | 1 | 16.7% |
Which technologies does Cantex Pharmaceuticals, Inc. patent most?
Top 3 of 3 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard
Velocity Growing
Frequently Asked Questions
How many patents does Cantex Pharmaceuticals, Inc. hold?
Cantex Pharmaceuticals, Inc. holds 6 US granted patents filed between 2016 and 2023, spanning 3 technology areas.
What is Cantex Pharmaceuticals, Inc.'s Innovation Score?
Cantex Pharmaceuticals, Inc. has an Innovation Score of 30.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Cantex Pharmaceuticals, Inc. focus on?
Cantex Pharmaceuticals, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 6 patents. The company has filed patents in 3 CPC subclasses total.
Is Cantex Pharmaceuticals, Inc.'s patent filing rate increasing or decreasing?
Cantex Pharmaceuticals, Inc.'s recent filing velocity is +0% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for Cantex Pharmaceuticals, Inc.'s patents?
Cantex Pharmaceuticals, Inc.'s patents average 18.5 claims each. This falls within the standard range, providing solid legal coverage.
How is the Cantex Pharmaceuticals, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Cantex's 6 grants land it in the top 65% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Cantex ranks #39,495 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.